ARTBIO Forms Strategic Alliance with 3B Pharmaceuticals
ARTBIO has recently announced a significant collaboration combining its innovative AlphaDirect™ platform for alpha radioligand therapies with the expertise of 3B Pharmaceuticals in peptide radioligand discovery and development. This partnership aims to advance a cutting-edge therapy targeting solid tumors, an area with considerable unmet medical needs.
A Focused Approach to Cancer Treatment
Through this unique collaboration, ARTBIO secures an exclusive global license for an innovative program that is nearing clinical development. The goal is to tackle a first-in-class target specifically designed for solid tumor indications. With pressing medical demands in this realm, ARTBIO's initiative signifies an essential step toward providing therapeutic alternatives for patients.
Enhancing the Pipeline
This partnership strategically enhances ARTBIO's portfolio by introducing a highly differentiated program concentrated on a novel target, positioning it ideally for 212Pb-based alpha radioligand therapy. 212Pb possesses a favorable clinical profile, characterized by its short half-life and effective energy delivery to tumors, making it a prime candidate for this therapy.
Statements from Company Leaders
Dr. Emanuele Ostuni, the CEO of ARTBIO, emphasized the significance of this licensing as a move towards broadening their impact beyond prostate cancer. He stated, "By exploring targets that are new to radioligand therapies in conjunction with 3BP’s extensive experience, we are positioned to unlock crucial new therapeutic avenues that could greatly benefit patients facing various cancers."
Potential Across Multiple Indications
The agreement promises to deliver a novel treatment path for several solid tumor types. Many patients currently lack effective treatment methods, and radioligand therapies have not yet been fully utilized in these cases. Plans for clinical development are slated to commence in the near future, with both organizations expected to contribute their expertise to refining the treatment's therapeutic profile.
Pioneering New Oncology Treatments
Dr. Ulrich Reineke, Managing Director of 3B Pharmaceuticals, commented on the collaboration, saying, "By merging our innovative discovery platforms, we are set to redefine the approaches used in treating solid tumors. This partnership is more than just a licensing agreement; it's the initiation of a pioneering journey toward better patient outcomes in oncology."
About ARTBIO
ARTBIO is a pioneering clinical-stage radiopharmaceutical company dedicated to transforming cancer care by developing a new class of alpha radioligand therapies (ARTs). Their unique methodology is characterized by selecting optimal alpha-precursor isotopes like 212Pb, alongside identifying specific targets to optimize therapeutic effectiveness and safety. The company’s proprietary AlphaDirect™ technology facilitates the reliable production and delivery of ARTs, supporting multiple ongoing pipeline programs, including its lead initiative, AB001, which is currently in first-in-human trials. ARTBIO’s legacy stems from nearly a century of innovative radiation therapy research at the University of Oslo and Norway's Radium Hospital.
About 3B Pharmaceuticals
3B Pharmaceuticals GmbH is at the forefront of developing advanced therapeutic and diagnostic radiopharmaceuticals targeted at oncology applications. Their dedicated platform has enabled the creation of a diverse pipeline of novel compounds, aimed at both innovative and established drug targets to deliver therapeutic radioisotopes directly to tumors. The cornerstone of their mission is to elevate the standard of care in precision oncology through groundbreaking nuclear medicine approaches that meet unmet medical needs.
Frequently Asked Questions
What is the purpose of the partnership between ARTBIO and 3B Pharmaceuticals?
The partnership aims to develop a first-in-class alpha radioligand therapy focused on treating solid tumors, utilizing ARTBIO’s innovative platform and 3B’s expertise.
How does 212Pb contribute to the therapy?
212Pb is chosen for its short half-life and ability to deliver targeted energy to tumors, making it ideal for effective radioligand therapy.
When will clinical development begin for the new therapy?
Clinical development for the licensed program is expected to initiate in the near future, starting in 2025.
What is ARTBIO's main focus in cancer treatment development?
ARTBIO is focused on expanding beyond prostate cancer, developing therapies that target various cancers with high unmet medical needs.
Where can I find more information about ARTBIO and 3B Pharmaceuticals?
Information about ARTBIO can be found on their official website, while details about 3B Pharmaceuticals are available on their dedicated platform for public engagement.
